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There are several groups of medically important araneomorph and mygalomorph spiders 
responsible for serious systemic envenomation. These include spiders from the genus Latrodectus 
(family Theridiidae), Phoneutria (family Ctenidae) and the subfamily Atracinae (genera Atrax 
and Hadronyche). The venom of these spiders contains potent neurotoxins that cause excessive 
neurotransmitter release via vesicle exocytosis or modulation of voltage-gated sodium channels. 
In addition, spiders of the genus Loxosceles (family Loxoscelidae) are responsible for significant 
local reactions resulting in necrotic cutaneous lesions. This results from sphingomyelinase D 
activity and possibly other compounds. A number of antivenoms are currently available to treat 
envenomation resulting from the bite of these spiders. Particularly efficacious antivenoms are 
available for Latrodectus and Atrax/Hadronyche species, with extensive cross-reactivity within 
each genera. In the case of Latrodectus antivenoms this is of considerable importance in countries 
where antivenom is unavailable or where certain antivenoms are associated with an unacceptably 
high risk of adverse reactions. Moreover, Latrodectus and Atrax antivenoms appear to be 
effective in the treatment of envenomation by closely related Steatoda spiders (family 
Theridiidae) or the un-related spider Missulena bradleyi (family Actinopodidae), respectively. 
The effectiveness of Loxosceles antivenom in the treatment of the necrotic arachnidism resulting 
from the bite of recluse spiders is less clear mainly due to late presentation of victims. Antivenom 
is also available for Phoneutria envenomation but is reserved only for severe cases. 
Key Words: Envenomation; Spiders; Antivenom; Latrodectus; Phoneutria; Steatoda; Atrax; 
Hadronyche; Missulena; Loxosceles. 
  
INTRODUCTION 
Although most cases of spider bite result in minimal if any significant clinical 
consequences, there are a small number of spiders that may produce either serious 
systemic clinical envenomation syndromes or significant local reactions. The true 
incidence of spider bite, spider envenomation and death resulting from spider bite in 
humans world-wide is unknown and more than likely under-represented due to the 
voluntary nature of most reporting processes. This review will discuss the role and 
effectiveness of spider antivenoms for treatment of envenomation by medically important 
spiders of the genera Latrodectus, Loxosceles, Phoneutria and the subfamily Atracinae 
(genera Atrax and Hadronyche). 
 
HUMAN ENVENOMATION BY THERIDIID SPIDERS 
Distribution of Latrodectus Species 
Arguably the most clinically significant group of spiders are the widow spiders (Araneae: 
Araneomorphae: Theridiidae), of the genus Latrodectus. This genus is comprised of 
multiple species found on all continents excluding Antarctica (Bucherl, 1971) (see Figure 
1). Little is known about the true incidence of envenomation following the bite of Widow 
spiders due to a lack of organized data collection in most regions of the world. In 
Australia, an estimate of two to three thousand L. hasselti (Red-back spider) bites per year 
has been made. Clinically significant Red-back spider envenomation requiring antivenom 
therapy occurs in around 20% of these cases (Jelinek et al., 1989; White, 1998). In the 
United States, reports to the American Association of Poison Control Centers in 1997 
revealed 2757 cases of Widow spider bite, but with only 0.004% defined as having a 
‘major outcome’ (Litovitz et al., 1998). 
  
Latrodectism 
Although rarely fatal, envenomation by Latrodectus spp. may result in an incapacitating 
syndrome of severe local, regional, or systemic pain and autonomic features called 
‘latrodectism’ which, if left untreated, may last for several days or weeks (Maretic, 1983; 
White et al., 1995). The syndrome may vary in severity depending on the species and size 
of the spider, the season of the year, and the amount of venom injected but appears to be 
similar regardless of the geographic location of the spider (Bogen, 1926; Keegan et al., 
1960; Maretic, 1983; McCrone, 1964; Moss and Binder, 1987; Muller, 1993; Sutherland 
and Trinca, 1978; Wiener, 1961a; Zukowski, 1993). 
The initial bite of a Widow spider is often described as initially feeling like a bee sting 
(Bogen, 1926; Ingram and Musgrave, 1933; Maretic, 1983; Sutherland and Trinca, 1978). 
Most commonly local pain, sweating, erythema, and piloerection are noted at the bite site 
within 1 hour of exposure (Maretic, 1983; Muller, 1993; Sutherland and Trinca, 1978; 
Zukowski, 1993). Clinical features may remain isolated to the site of the bite or less 
commonly progress to become regional or systemic (see Table 1). Progression to systemic 
toxicity may occur at a variable rate either rapidly or over a few hours (Clark et al., 1992; 
Jelinek et al., 1989; Maretic, 1983; Timms and Gibbons, 1986; White et al., 1995). The 
risk of systemic toxicity is greater in the very young, the very old, and those with any 
premorbid chronic medical illnesses. The natural progression of envenomation is a 
gradual diminution of symptoms and signs over several days to weeks although, 
uncommonly, features of envenomation may persist for months. Fortunately, however, 
there have been are no reports of death from widow spider envenomation in the medical 
literature in the last 40 years. This is probably related to both an improvement in medical 
supportive and resuscitative therapies as well as the development of specific antivenom 
therapies (see Treatment and Management of Latrodectism). 
Table 1. Summary of the local, regional, and systemic features of latrodectism.  
Signs and symptoms 









• Piloerection   
• Sweating   
• Regional sweating 
to limb or specific 
region of body   
• Generalized 
muscle pain   








• Tachycardia   
• Hypertension   
• Nausea   
• Priapism 





• Vomiting   
• Insomnia   
• Dizziness   
• Dyspnea   
• Restlessness 
• Mild pyrexia 
• Paresthesia 
• Pavor mortisb   
• Facies latrodectismicac 
 
aIncludes bitten limb and can also occur in contralateral limb.   
bFeeling of impending doom.   
cAn unusual pattern of facial muscle grimacing, trismus, blepharoconjunctivitis, and facial 
flushing.   
Data taken from: Bogen, (1926), Jelinek et al. (1989), Maretic, (1983), Muller, (1993), Russell, 
(1962), Sutherland and Trinca, (1978), Timms and Gibbons, (1986), White, (1985), White et al., 
(1995), Zukowski, (1993). 
 
The venoms of all Latrodectus species are thought to contain similar toxic components. 
This assertion is based on two significant observations. 1) Envenomation resulting from 
the bite of any Widow spider results in a similar clinical picture regardless of the species 
of spider. 2) Widow spider antivenoms produced using the venoms of specific 
Latrodectus species reverse the effects of envenomation from other Latrodectus spiders 
both in experimental animal models and in the clinical setting (see Antivenom Cross-
Reactivity with Other Latrodectus Venoms). The toxin believed to be responsible is the 
vertebrate-specific, α-latrotoxin (α-LTx), a 120 kDa toxin that acts selectively on 
presynaptic nerve endings causing massive release of neurotransmitters by synaptic 
vesicle exocytosis (for a review see Sudhof (2001). 
 
Treatment and Management of Latrodectism 
Treatment with locally produced species-specific antivenom is regarded as the principal 
therapy in countries where antivenom is available. Specific antivenoms raised against the 
venoms of various Latrodectus species have been developed in many regions of the world 
(Theakston and Warrell, 1991) (see Table 2). Nevertheless, there are large areas where no 
local antivenom is available. These include Central Asia, the Middle East, northern Africa 
and Southeast Asia, and also Europe where antivenom production ceased with the 
outbreak of the Balkan conflict in the 1990s. 
Antivenom Effectiveness 
Antivenom therapy is considered the most effective treatment for the symptoms and signs 
of latrodectism (Bogen, 1926; Clark et al., 1992; Russell et al., 1979; Sutherland and 
Trinca, 1978; Wiener, 1956; Wiener, 1961a). Patients receiving antivenom therapy are 
more likely to be discharged home directly from emergency departments and have much 
shorter hospital stays than those receiving supportive measures alone (Clark et al., 1992). 
Additionally, relief of symptoms usually occurs within 1 to 2 hours of antivenom 
administration with all available antivenoms (Clark et al., 1992; Maretic, 1983; Muller, 
1993; Sutherland and Trinca, 1978). 
Table 2. Cross reactivity of Latrodectus antivenoms. 
   Cross-neutralization of venom/toxin 
Venom that 








Mice (in vivo) 
 
L. mactans Merck & Co., Inc., West Point PA, 
USA 
Instituto Nacional de 
Microbiologia, Buenos Aires, 
Argentina 
Instituto Bioclon, Calzada de 


















L. indistinctus South African Institute for Medical 
Research, Rietfontein, Edenvale, 
Transvaal, South Africa 
Equine IgG L. geometricusa  – 
L. hasselti Commonwealth Serum 
Laboratories, Melbourne, Australia 







L. hesperusd,e   
L. tredecimguttatusd 
L. lugubrisd   
α-LTxd   
Steatoda grossag 
L. tredecimguttatus Institute of Immunology, Zagreb, 
Croatiab 
Ovine IgG  L. mactansf   
L. hasseltif 
aNormal clinical indication for usage. 
bNo longer available.   
cData taken from: Wiener (1961a).   
dData taken from: Graudins et al. (2001). 
eData taken from: Daly et al. (2001). 
fData taken from: Keegan (1955). 
gData taken from: Graudins et al. (2002a). 
hData taken from: South et al. (1998). 
 
Generally, the dose of Widow spider antivenom required to treat envenomation is 
reported as one to two ampoules of antivenom for most formulations (Clark et al., 1992; 
Jelinek et al., 1989; Maretic, 1983; Sutherland and Trinca, 1978; Wiener, 1956; Wiener, 
1961a). Uncommonly, some patients have required up to 8 vials of Australian red-back 
spider antivenom to reverse the features of L. hasselti envenomation (Graudins et al., 
1999). Importantly antivenom may reverse envenomation presenting to hospital many 
days or even weeks after exposure (Allen and Norris, 1995; Banham et al., 1994; Wiener, 
1956). 
Antivenom Side-Effects 
The incidence of severe anaphylactic reactions occurring with different antivenom 
formulations appears to vary. This has resulted in an inconsistency in the threshold for use 
of antivenom from region to region. In the United States, there appears to be the greatest 
reluctance by physicians to use specific immunotherapy. This is most likely due to 
isolated case reports of death following administration of North American widow spider 
antivenom (Clark et al., 1992) and an extrapolated risk of anaphylaxis calculated from the 
use of crotalid polyvalent snake antivenom (Spaite et al., 1988). Clark et al. observed an 
8% incidence of allergic reactions (urticaria and bronchospasm) with North American 
widow spider antivenom use (Clark et al., 1992). This has resulted in alternative therapies 
being employed however large case studies have shown that these are not as effective as 
antivenom therapy (Clark et al., 1992). Manufacturer recommendations for the use of this 
antivenom suggest that it should be reserved for ‘severe cases’ of envenomation or those 
occurring at the extremes of age. However, these recommendations are conservative and 
could result in a significant number of patients suffering from prolonged envenomation if 
left untreated. 
In Australia, on the other hand, Red-back spider antivenom, an equine derive F(ab)2 
fragment, is the most commonly used antivenom in the country (Ho et al., 1999; 
Sutherland and Trinca, 1978; White, 1998). Clinicians will commonly administer 
antivenom to any patient with persisting local features of envenomation, regional 
symptoms or signs and any case of systemic envenomation. Mild allergic reactions are 
reported to occur in 0.54% of cases (half of these were the result of administration of 
undiluted antivenom intravenously), with a 1.4% incidence of serum sickness (Sutherland 
and Trinca, 1978). Severe anaphylaxis or death has not been reported following Red-back 
spider antivenom use. The reported incidence of allergic reactions is probably over-
represented with this antivenom as it is based on voluntary reporting of antivenom use to 
the manufacturer (Ho et al., 1999). 
Antivenoms in general contain a significant amount of protein with anti-complement 
activity that may result in anaphylactoid reactions if infused rapidly (Sutherland, 1977). 
This activity is reported to be reduced in trypsin-digested antivenoms such as Red-back 
spider antivenom. It may be much greater in antivenoms produced as crude hyperimmune 
equine sera, such as North American widow spider antivenom (Sutherland, 1977). Little 
is documented about the use of antivenom and the incidence of adverse reactions with 
antivenom formulations in other parts of the world. 
 
Antivenom Cross-Reactivity with Other Latrodectus Venoms 
Widow spider antivenoms are commonly produced from animals exposed to one specific 
Latrodectus venom. Nevertheless, it has been observed that species-specific antivenoms 
are capable of treating envenomation from more than one kind of Widow spider. Indeed 
clinical observations of antivenom use around the world and in vivo studies in mice 
suggest that it may be possible to use antivenom raised to the venom of related widow 
spiders, from other continents, to treat widow spider envenomation (see Table 2). These 
observations suggest that all Widow spider antivenoms may be capable of reversing 
clinical envenomation by any other Latrodectus species worldwide. This is supported by 
the observation that L. hasselti antivenom can neutralize the toxicity of α-LTx derived 
from L. tredecimguttatus venom (Graudins et al., 2001). 
 
Use of Widow Spider Antivenom in the Treatment of Envenomation by Related 
Theridiid Spiders 
The ‘Cupboard’, ‘Brown house’, or ‘False widow’ spider are all descriptive terms used to 
encompass various species of Steatoda (Araneae: Araneomorphae: Theridiidae), close 
relatives of widow spiders. They are found worldwide and are endemic to most continents 
(Cavalieri et al., 1987; Korszniak and Story, 1994; Main, 1984; Rutherford and 
Sutherland, 1989; South et al., 1998; Warrell et al., 1991). In general, bites from Steatoda 
spp. result in minor local symptoms not requiring any specific intervention. However, 
they have been implicated in a small number of cases of systemic envenomation in 
humans, also called ‘steatodism’ (Graudins et al., 2002a; Rutherford and Sutherland, 
1989; South et al., 1998; Warrell et al., 1991). The envenomation syndrome observed in 
these severe cases is similar to that of latrodectism adding further support to in vitro 
observations of an α-LTx-like effect by Steatoda venom (Einhorn and Hamilton, 1973; 
Einhorn and Hamilton, 1974; Frontali et al., 1976; Gorio et al., 1978; Graudins et al., 
2002a; Korszniak and Story, 1994). Red-back spider antivenom has been successfully 
administered in two cases of systemic steatodism with resolution of all features of 
envenomation (Graudins et al., 2002a; South et al., 1998). In vitro toxicity data supports 
this clinical observation, and suggests that S. grossa venom is immunogenically and 
chromatographically similar to Latrodectus venoms (Graudins et al., 2002a). 
 
HUMAN ENVENOMATION BY AUSTRALIAN FUNNEL-WEB SPIDERS 
Distribution of Atrax and Hadronyche Species 
Australian funnel-web spider venom probably represents one of the most toxic spider 
venoms known to affect humans. Australian funnel-web spiders (Araneae: 
Mygalomorphae: Hexathelidae: Atracinae) are a relatively large group of spiders that 
include the genera Atrax and Hadronyche. These genera comprise of over 35 different 
species of that are mainly located along the southeastern seaboard of continental Australia 
and Tasmania (Gray, 1987; White et al., 1995) (see Figure 2). 
 
Clinical Features of Envenomation by Atrax and Hadronyche Species 
The medical literature contains numerous reports describing severe male Atrax robustus 
envenomation and death in humans (Sutherland, 1983a; Torda et al., 1980; Wiener, 
1961b). Life-threatening envenomation indistinguishable to that of A. robustus resulting 
from the bite of Hadronyche species has also been observed and appears to be becoming 
more common due to rapid population spread (Dieckman et al., 1989; Harrington et al., 
1999; Miller et al., 2000). These reports suggest that the envenomation syndrome is 
similar between species and all Funnel-web spiders are thought to have venom potentially 
toxic to primates and man (White et al., 1995). Despite this, Funnel-web envenomation 
remains an uncommon phenomenon. An estimate of envenomation occurring in one out 
of ten bites has been made and that there are approximately 30 to 40 funnel-web bites 
with 3 to 4 cases of envenomation per year (White et al., 1995). 
Systemic envenomation, while rare, may develop extremely rapidly and has been reported 
as quickly as 10 minutes following a bite (White et al., 1995; Sutherland, 1983a). 
Children may deteriorate rapidly and death may result in 1 to 2 hours if left untreated 
(Sutherland, 1983a). Death usually results from progressive, irreversible hypotension, or 
possibly raised intracranial pressure resulting from cerebral edema (Fisher et al., 1980; 
Torda et al., 1980) (see Table 3). 
The envenomation syndrome is due to the presence of δ-atracotoxins (formerly robustoxin 
and versutoxin) that are 4–5 kDa peptide neurotoxins found in Funnel-web spider venoms 
(Brown et al., 1988; Sheumack et al., 1985; Szeto et al., 2000). These all act by slowing 
sodium current inactivation (Nicholson et al., 1994, 1996, 1998; Szeto et al., 2000) 
resulting in spontaneous repetitive firing of action potentials (Grolleau et al., 2001). 
Ultimately, excessive neurotransmitter release results in muscle fasciculation and 
autonomic effects on the cardiovascular system and exocrine glands. 
Table 3. Summary of clinical features of funnel-web spider envenomation. 
Local effects • pain 
• piloerection 
• sweating 
• muscle fasciculation 
Systemic effects 
• circumoral paresthesia 






• generalized muscle 
fasciculation and weakness 
• tachycardia 
• hypertension 





• cerebral edema 
• metabolic acidemia. 
Late effects1 
• persistent hypotension 
• unremitting coma 
• coagulopathy 




aCommonly not seen in patients receiving early treatment with antivenom. 
  Data taken from Fisher et al. (1980), Sutherland (1983a), Torda et al. (1980). 
 
Treatment and Management of Atrax and Hadronyche Envenomation 
First-aid for Funnel-web spider bite may be a life saving maneuver in patients who will 
require transport to hospital. Application of a pressure immobilization bandage inhibits 
the development of envenomation and has been proven to be clinically effective in the 
prevention of Funnel-web spider envenomation (Sutherland and Duncan, 1980; 
Sutherland et al., 1980). Prolonged application of a pressure immobilization bandage for 
up to 24 hours may result in apparent local neutralization of venom (Sutherland et al., 
1980). It is hypothesized that the venom is slowly inactivated in the tissues, possibly by 
hydrolysis (Sutherland et al., 1980). 
Antivenom Effectiveness 
In view of the life-threatening envenomation syndrome that may result from the bite of 
Funnel-web spiders, a purified rabbit IgG antibody to the venom of the male A. robustus 
was developed in 1980 by Commonwealth Serum Laboratories in Melbourne, Australia 
(Fisher et al., 1981; Hartman and Sutherland, 1984; Sutherland, 1980; Sutherland et al., 
1981). Antivenom therapy has markedly shortened the course of envenomation and 
resulted in reduced hospital stay as well as reduced the morbidity and mortality from 
funnel-web spider envenomation (Fisher et al., 1981; Sutherland, 1983a). Antivenom 
treated patients are commonly discharged from hospital within 1 to 3 days of antivenom 
treatment. Prior to antivenom availability the average length of hospital stay for severe, 
non-fatal cases of envenomation was 14 days (Torda et al., 1980). 
The antivenom has also been reported to be effective in reversing envenomation from 
other species of Funnel-web spider including H. formidabilis, H. infensa, H. species 14, H. 
cerberea and H. versuta (Dieckman et al., 1989; Harrington et al., 1999; Miller et al., 
2000). More recently, Graudins et al. (2002b) have shown that Funnel-web spider 
antivenom can neutralize the toxicity of a number of other Hadronyche and Atrax spp. 
venoms from both male and female spiders in vitro. 
Antivenom Side-Effects 
Although figures are unavailable, the incidence of allergic reactions to funnel-web 
antivenom appears to be low. Only one case of delayed serum sickness has been 
documented one week following treatment with Funnel-web spider antivenom (Miller et 
al., 1999). 
Use of Funnel-Web Spider Antivenom for the Treatment of Envenomation by Mouse 
Spiders (Genus Missulena) 
There are currently 11 recognized species of mouse spider in the genus Missulena 
(Araneae: Mygalomorphae: Actinopodidae) with a wide-spread distribution over 
mainland Australia (Faulder, 1995; Main, 1985; Main, 1996). Envenomation is 
uncommon but may resemble systemic funnel web spider envenomation in severe cases 
(Faulder, 1993). Funnel-web spider antivenom has been used to successfully treat an 
envenomation syndrome from the bite of a male Eastern mouse spider (Missulena 
bradleyi, see Figure 3) (Underhill, 1987). Subsequently a δ-atracotoxin-like action of the 
venom to slow sodium channel inactivation has been identified and the action of 
antivenom to neutralize the venom confirmed in isolated nerve-muscle preparations (Rash 
et al., 2000). 
 
HUMAN ENVENOMATION BY LOXOSCELES SPIDERS 
The second most medically important group of spiders are from the genus Loxosceles 
(Araneae: Araneomorphae: Loxoscelidae) otherwise known as ‘recluse‘, ‘violin’ or 
‘gaucho’ spiders, These spiders can cause necrotic arachnidism, otherwise known as 
loxoscelism, a form of necrotic cutaneous lesion. Less commonly they can cause a 
systemic illness that is sometimes fatal. 
Distribution of Loxosceles Species 
They are distributed in the southern states of North America, as well as Central and South 
America, Europe, southern Africa, Middle East and parts of Asia and have been 
accidentally introduced into Australia and some other countries (see Figure 4). Although 
there are over 50 species only a few have been implicated in loxoscelism. 
Loxoscelism 
There are two basic forms of loxoscelism: cutaneous (the more frequent form) and 
viscerocutaneous which is relatively uncommon to rare (see Table 4). Diagnosis of 
envenomation is usually based on clinical presentation since the spider is not usually 
available for identification. Despite this enzyme immunoassay ELISAs have been 
successful in detecting Loxosceles venom in necrotic skin lesions (Cardoso et al., 1990) 
and specific IgG antibodies in patients (Barbaro et al., 1992a) although the latter has not 
proved effective so far. In addition a passive haemagglutination inhibition assay for L. 
reclusa venom appears to show promise for the confirmation of loxoscelism (Barrett et al., 
1993). 
Sequelae of the cutaneous form include disfiguring scars (Schenone et al., 1989), 
persistent damage to underlying nerves, hyalinizing panniculitis and myonecrosis (Bascur 
et al., 1992), pseudoepitheliomatous hyperplasia and pyoderma gangrenosum (Ingber et 
al., 1991). In the rare cases of lethal envenomation, typically in children, death is 
associated with acute renal failure mainly due to hemolysis (Futrell, 1992). 
 
Table 4. Summary of the clinical features of cutaneous and viscerocutaneous loxoscelism. 
Form of loxoscelism Signs and Symptoms 
Cutaneous 
• painless bite with pain 
intensifying (probably due to 
ischemia) 
• itching and tenderness  
• nonspecific erythema  
• local edema  
• hemorrhagic mottling areas 
with regions of ischemia 
• fever 
• dry necrosis with underlying 
ulceration 
Viscerocutaneous 
As above plus: 
• fever 
 





• disseminated intravascular 
coagulation 
• acute renal failure 
Taken from Bascur et al. (1992), Futrell, (1992), Schenone et al. (1989). 
 
The dermonecrotic, platelet aggregative and intravascular hemolytic activity of 
Loxosceles spp. venom is due to the presence of 31–35 kDa sphingomyelinase D that can 
account for death of laboratory animals (Babcock et al., 1981; Barbaro et al., 1992b; 
Futrell, 1992; Kurpiewski et al., 1981; Tambourgi et al., 1998). Polymorphonuclear 
leucocytes are also important in the development of the necrotic lesions (Smith and Micks, 
1979; Young and Pin, 1988) and appear to be related to the presence of circulating 
complement (Ward and Cochrane, 1965) although the extent of complement pathway 
involvement is still uncertain (see Futrell (1992)). 
 
Treatment and Management of Loxoscelism 
The Instituto Butantan (Sao Paulo, Brazil) has developed a specific antivenom to L. 
reclusa (soro-antiloxoscelico) that is used routinely in patients with acute cutaneous 
lesions and/or signs of systemic toxicity. Nevertheless the antivenom has shown limited 
success in reversing symptoms, mainly due to late presentation of victims (Futrell, 1992). 
However, a recent study employing polyclonal anti-Loxosceles Fab fragments indicated 
that administration of antivenom within 4 hours reduced Loxosceles-induced 
dermonecrotic lesions in rabbits (Gomez et al., 1999). This maybe why the effectiveness 
of the antivenom is poor clinically. A polyvalent antivenom (soro-antiarachnidico 
polyvalente) is also available for bites of other species of Loxosceles found in Brazil 
including the three most common and clinically important species L. intermedia, L. 
gaucho and L. laeta (Braz et al., 1999; Mota et al., 1995). However antivenom is not 
available in most regions where these spiders are found. 
To date the treatment for envenomation consists of general wound management and 
documentation of the extent of the lesion. Blood and urine tests are also performed to 
exclude viscerocutaneous involvement that requires supportive measures including blood 
transfusion and systemic antibiotics. Occasionally antihistamines, dapsone, hyperbaric 
oxygen and even cautious use of surgical excision have been tried. However systemic 
corticosteroids are now generally not recommended (for a review see White et al. (1995)). 
 
ENVENOMATION AND TREATMENT OF PHONEUTRIA BITES 
Distribution of Phoneutria Species and Clinical Features of Envenomation 
The ‘Banana’ or ‘armed’ spiders of the genus Phoneutria (Araneae: Araneomorphae: 
Ctenidae) are mainly confined to the eastern areas of Central and South America. In 
particular they represent the most common cause of spider bites presenting to hospitals in 
Brazil (White et al., 1995). The venom appears to contain many neurotoxins some of 
which are capable of causing a slowing of inactivation and a hyperpolarizing shift in the 
voltage dependence of activation of voltage-gated sodium channels (for a review see 
Cordeiro et al. (1995)). This is thought to result in an increased release of peripheral 
neurotransmitters, particularly acetylcholine and catecholamines. Pain is the most 
common symptom of envenomation but autonomic features also predominate (see Table 
5). 
  
Table 5. Summary of the clinical features of Phoneutria envenomation. 
 
Data adapted from White et al., 1995. 
 
Treatment and Management of Phoneutria Envenomation 
Treatment is based on the severity of envenomation with symptomatic treatment 
involving the use of a local anesthetic block to relieve pain. An equine antivenom is 
available (soro-antiarachnidico polyvalente, Instituto Butantan, Sao Paulo, Brazil) which 
contains an anti-Phoneutria fraction. However it is reserved only for moderate to severe 
cases. Therefore in Hospital Vital Brazil in Sao Paulo it is used in less than 5% of patients, 
being mainly children under the age of 7 and elderly patients (White et al., 1995). Since 




Antivenoms are available and particularly effective for the treatment of bites from 
Latrodectus and Atrax/Hadronyche spp. and most likely Steatoda and Missulena 
envenomation. The cross-reactivity of certain Latrodectus antivenoms is of particular 
importance especially where antivenoms are unavailable or associated with high risk of 
adverse reactions. The role of antivenom therapy in the treatment of Loxosceles 
envenomation, however, is less clear typically due to the late presentation of victims 
nevertheless it can be useful in severe Phoneutria envenomation. 
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Figure 1. Worldwide distribution of some species of Latrodectus. Medically important species 
are highlighted in bold text. Data from Bucherl (1971), Lucas (1988), Maretic (1978), Newlands 
and Atkinson (1988), Platnick (1990), Sutherland (1983b). 
  




Figure 3. The male (left) and female (right) Eastern mouse spider (Missulena bradleyi). Scale bar 
represents 1 cm. Photo courtesy of David Humfrey. 
  
Figure 4. Approximate worldwide distribution of some important species of Loxosceles. 
Medically important species are highlighted in bold text. Data from Anderson (1982), Barbaro et 
al. (1992a), Berger (1973), Bucherl (1971), Futrell (1992), Gajardo-Tobar (1966), Lucas (1988), 
Newlands and Atkinson (1988), Newlands and Atkinson (1990), Rees et al. (1987), Schenone 
and Suarez (1978), Schenone et al., (1975), Schenone et al. (1989), Southcott (1976), and 
Wasserman and Anderson (1983). 
 
